Abstracts | 71 groups, only KYN correlated with SERT in the midbrain in HC (ρ=-0.544, p=0.001). A further analysis showed that, at TBI > 0.06, midbrain SERT correlated with TRP (ρ=-0.900, p=0.037), KYN (ρ=-0.900, p=0.037), and TBI (ρ=0.900, p=0.037) in HC. However, this could not be replicated in MDD. Conclusion: Our results are the first to demonstrate complicated interactions between TRP metabolism and SERT in different brain regions. The significance of the association between TRP metabolism and SERT in HC, in particular at different levels of TBI, is warrant for further study.
Abstract
There is an unmet need to improve the diagnosis of treatment-resistant depression (TRD). Current diagnostic metrics fail to accurately identify patients who will not respond to first-line and subsequent therapeutic strategies. However, there is increasing evidence to support the concept of biomarkers as a means to improve diagnostic precision and refine treatment options for TRD. MicroRNAs are small nucleotide sequences that regulate gene expression and accumulating evidence has linked their presence in the periphery to the pathophysiology of depression. Thus, we hypothesised that microRNAs could serve as biomarkers for TRD. We further proposed that baseline microRNA expression could predict remission with ketamine infusions (KET) or electroconvulsive therapy (ECT).
To test these hypotheses, we studied the peripheral micro-RNA expression profiles of healthy controls (n=17) and patients (n=30) with TRD who received treatment with infusions of KET (0.5mg/kg IV over 40 min) or ECT (average of 8.9 sessions per patient). Remission following treatments was defined as at least a 50% reduction in the Hamilton Depression Rating Scale scores. RNA was isolated from blood samples collected at baseline and after treatments. To determine differences in microRNA expression, microarray (Exiqon) and qPCR analyses were performed on samples.
The baseline expression of let-7b was significantly reduced by 40% in TRD patients. Bioinformatic analysis revealed that let7b regulates the expression of 25 genes in the PI3k-Akt-mTOR signaling pathway which has previously been reported to be dysfunctional in depression. KET and ECT both had positive effects in attenuating depression symptomatology and 72% of patients achieved remission. However, we found no microRNAs altered by treatment and remission could not be predicted from baseline microRNA expression profiles.
Our data suggests that let-7b is a putative peripheral traitbiomarker for TRD. Experiments are on-going to study the functional effects of let-7b and how they relate to the pathophysiology of depression.
PS194
Discovery of serum protein biomarkers in drug-free patients with major depressive disorder (MDD) is a systemic and multifactorial disorder involving complex interactions between genetic predisposition and disturbances of various molecular pathways. Its underlying molecular pathophysiology remains unclear, and no valid and objective diagnostic tools for the condition are available. Methods: We performed large-scale proteomic profiling to identify novel peripheral biomarkers implicated in the pathophysiology of MDD in 25 drug-free female MDD patients and 25 healthy controls. First, quantitative serum proteome profiles were obtained and analyzed by liquid chromatography-tandem mass spectrometry using serum samples from 10 MDD patients and 10 healthy controls. Next, candidate biomarker sets, including differentially expressed proteins from the profiling experiment and those identified in the literature, were verified using multiple-reaction monitoring in 25 patients and 25 healthy controls. The final panel of potential biomarkers was selected using multiparametric statistical analysis. Results: We identified a serum biomarker panel consisting of six proteins: apolipoprotein D, apolipoprotein B, vitamin D3-binding protein, ceruloplasmin, hornerin, and profilin 1, which could be used to distinguish MDD patients from controls with 68% diagnostic accuracy. Our results suggest that modulation of the immune and inflammatory systems and lipid metabolism are involved in the pathophysiology of MDD. Conclusions: Our findings of functional proteomic changes in the peripheral blood of patients with MDD further clarify the molecular biological pathway underlying depression. Further studies using larger, independent cohorts are needed to verify the role of these candidate biomarkers for the diagnosis of MDD. Key words: Major depressive disorder, proteomics, immune system, inflammation, lipid metabolism
